NCT05081258

Brief Summary

Orofacial clefts are the second most common birth deformity and vary in etiology and phenotype, e.g. isolated cleft palate, cleft lip or cleft lip palate. Especially newborns with unilateral complete cleft lip and palate (UCLP) present severe facial asymmetries auch as a broad and flat ala of the nose, a deviation of the columella and the philtrum to the non cleft side. Since postnatal asymmetries can even remain after surgical lip closure in a alleviated shape, therapeutic presurgical orthodontic approaches to improve symmetrie of the nose and to achieve ideal conditions for lip surgery are essential. Presurgical orthodontic treatment for newborns with UCLP start within the first days after birth to separate oral and nasal cavitiy, to improve breathing and feeding and to regulate growth of the maxillary segments using passive appliances (passive Alveolar Molding (pAM)). An advanced and widely spread concept is the Nasoalveolar Molding (NAM) by Grayson, which was first introduced in 1993 as a palate plate combined with a nasal stent as a non-invasive presurgical appliance to stimulate growth of the nose and use the postnatal potential to modulate the nasal cartilage. The aim of the NAM therapy is to reduce nasal width, to reduce deviation of the columella to the non cleft side and to increase nostril height. However, due to inhomogeneous study designs and results, so far only a slightly positive effect using NAM therapy could be detected and prospective, randomized clinical trials are necessary. The aim of the study is to analyse and to compare the effects of pAM versus NAM treatment in newborns with UCLP in the first year of life. The following parameters will be analysed on defined study time points: nostril width, nasal morphology, cleft width, maxillary growth, statical and dynamical facial asymmetries and facial perception.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
6mo left

Started May 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
May 2022Nov 2026

First Submitted

Initial submission to the registry

August 4, 2021

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 18, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

May 1, 2022

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

May 18, 2022

Status Verified

May 1, 2022

Enrollment Period

4.5 years

First QC Date

August 4, 2021

Last Update Submit

May 17, 2022

Conditions

Keywords

passie Alveolar MoldingNasoalveolar MoldingMaxillary GrowthFacial Asymmetry

Outcome Measures

Primary Outcomes (2)

  • Columella Deviation Angle

    The change of the Collumella Deviation Angle from Baseline until surgical lip closure. The change of the Columella Deviation Angle will be measured digitally using 3D-scanned models from the nose (scans and impressions from the nose) and defined anatomical points placed by four raters. Sbalc (lNc) = Subalar point on the cleft side Sbalnc (lNnc) = Subalar point on the non-cleft side SN = Subnasal point sn'c (mNc) = Subnasale' point Prn = Pronasal point CDA = Columella Deviation Angle = Angle (°) between the columella axis (connecting line between SN and Prn) and Subalar base line (connecting line between Sbalc and Sbalnc) on the cleft side

    From baseline (after birth) until surgical lip closure (6 - 7 months of life)

  • Nostril Width on the cleft side

    The change of the Nostril Width on the cleft side from Baseline until surgical lip closure considering different time points. The change of the Nostril Width on the cleft side will be measured digitally using 3D-scanned models from the nose (scans and impressions from the nose) and defined anatomical points placed by four raters: Sbalc (lNc) = Subalar point on the cleft side Sbalnc (lNnc) = Subalar point on the non-cleft side SN = Subnasal point sn'c (mNc) = Subnasale' point Prn = Pronasal point NWc = Nostril Width on the cleft side = Distance (mm) of the connecting line between Sbalc and sn'c

    From baseline (after birth) until surgical lip closure (6 - 7 months of life)

Secondary Outcomes (6)

  • Nasal shape

    From baseline (after birth) until one year after surgical palate closure (24 months of life)

  • Nasal symmetry

    From baseline (after birth) until one year after surgical palate closure (24 months of life)

  • Alveolar cleft width and transversal/sagittal maxillary growth

    From baseline (after birth) until one year after surgical palate closure (24 months of life)

  • Alveolar symmetry and rotation of alveolar segments

    From baseline (after birth) until one year after surgical palate closure (24 months of life)

  • Statistical and dynamical facial asymmetries

    From baseline (after birth) until one year after surgical palate closure (24 months of life)

  • +1 more secondary outcomes

Study Arms (2)

NAM treatment

ACTIVE COMPARATOR

Study Group: newborns with UCLP will be treated with a palate plate with nasal stent (Nasoalveolar Molding = NAM)

Procedure: Nasoalveolar Molding

pAM treatment

SHAM COMPARATOR

Control Group: newborns with UCLP will be treated with a palate plate without nasal stent (passive Alveolar Molding = pAM)

Procedure: passive Alveolar Molding

Interventions

A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).

pAM treatment

A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).

NAM treatment

Eligibility Criteria

Age1 Day - 2 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • newborns/infants with non-syndromal (ns) unilateral cleft lip palate (UCLP)
  • signed informed consent by the parents or legal guardian

You may not qualify if:

  • newborns/infants with syndromal (s) unilateral cleft lip palate (UCLP)
  • insufficient adherence and compliance by the parents or legal guardian
  • withdrawal of informed consent by the parents or legal guardian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Orthodontics and Orofacial Orthopedics, University Hospital of Erlangen-Nurnberg

Erlangen, Bavaria, 91054, Germany

RECRUITING

MeSH Terms

Conditions

Cleft LipFacial Asymmetry

Interventions

Nasoalveolar Molding

Condition Hierarchy (Ancestors)

Lip DiseasesMouth DiseasesStomatognathic DiseasesMouth AbnormalitiesStomatognathic System AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Preoperative CarePerioperative CarePatient CareTherapeuticsSurgical Procedures, OperativeHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Corinna Seidel, Dr.

    Department of Orthodontics and Orofacial Orthopedics, University Hospital of Erlangen-Nurnberg

    STUDY DIRECTOR
  • Lina Gölz, Prof. Dr.

    Department of Orthodontics and Orofacial Orthopedics, University Hospital of Erlangen-Nurnberg

    STUDY DIRECTOR
  • Karin Strobel, Dr.

    Department of Orthodontics and Orofacial Orthopedics, University Hospital of Erlangen-Nurnberg

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: prospective, longitudinal, randomized, clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Orthodontist, Senior Physician

Study Record Dates

First Submitted

August 4, 2021

First Posted

October 18, 2021

Study Start

May 1, 2022

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

May 18, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations